estrogen therapy — Competitive Intelligence Brief

estrogen therapy (estrogen therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormone replacement therapy (HRT). Area: Endocrinology / Women's Health.

marketed Hormone replacement therapy (HRT) Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ) Endocrinology / Women's Health Small molecule

Target snapshot

estrogen therapy (estrogen therapy) — Beni-Suef University. Estrogen therapy replaces or supplements endogenous estrogen by binding to estrogen receptors (ERα and ERβ) throughout the body to restore hormonal balance.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
estrogen therapy TARGET	estrogen therapy	Beni-Suef University	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ)
Estradiol+MPA	Estradiol+MPA	Brigham and Women's Hospital	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha and beta; progesterone receptor
Transdermal strogen	Transdermal strogen	Parc de Salut Mar	marketed	Hormone replacement therapy (HRT) / Estrogen replacement	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Estradiol + Medroxy Progesterone Acetate	Estradiol + Medroxy Progesterone Acetate	Erasmus Medical Center	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR)
Tibolone plus Xiangshao granules	Tibolone plus Xiangshao granules	Peking Union Medical College Hospital	marketed	Hormone replacement therapy (HRT) / Selective tissue estrogenic activity regulator (STEAR)	Estrogen receptor, Progesterone receptor, Androgen receptor
Femoston® 1, Femoston® 2	Femoston® 1, Femoston® 2	Scientific Research Institute of Public Health, Russian Federation	marketed	Hormone replacement therapy (HRT)	Estrogen receptor (ER-α, ER-β) and progesterone receptor (PR)
Transdermal estrogen	Transdermal estrogen	University of Utah	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormone replacement therapy (HRT) class)

1. Anna Posadzy-Małaczyńska · 1 drug in this class
2. Beni-Suef University · 1 drug in this class
3. Brigham and Women's Hospital · 1 drug in this class
4. El Shatby University Hospital for Obstetrics and Gynecology · 1 drug in this class
5. Erasmus Medical Center · 1 drug in this class
6. Massachusetts General Hospital · 1 drug in this class
7. Myovant Sciences GmbH · 1 drug in this class
8. Peking Union Medical College Hospital · 1 drug in this class
9. Scientific Research Institute of Public Health, Russian Federation · 1 drug in this class
10. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 drug in this class